Experimental Drug Shows Promise in Targeting Genetic Roots of High Blood Fats

An experimental drug, TLC-2716, is raising hopes for a new approach to reducing blood fats associated with deadly heart diseases.

Early clinical trial results showed the oral medication successfully lowered triglyceride levels by approximately 40% and reduced remnant cholesterol by over 60% after meals.

The research team, led by scientist Johan Auwerx at the Swiss Federal Institute of Technology in Lausanne, explained that metabolic disorders occur when fat production exceeds the body's ability to consume it, leading to accumulation on artery walls and the formation of plaques that can cause atherosclerosis, coronary heart disease, acute pancreatitis, and non-alcoholic fatty liver disease.

The trial, conducted on 100 healthy volunteers, aimed to test the drug's effect on a vital receptor known as LXR alpha, produced by the NR1H3 gene. This receptor acts as a regulatory switch for fat production and processing in the liver and intestines.

During the 14-day trial, participants received daily doses of the drug or a placebo. Results indicated that higher doses reduced triglycerides by up to 38.5%, while remnant cholesterol decreased by 61% after meals.

Researchers noted that all doses were safe and well-tolerated, and the oral administration offers a practical advantage in terms of ease of use and potential combination with other lipid-lowering medications.

Researchers analyzed extensive genetic databases to pinpoint the role of the LXR alpha receptor in lipid disorders. They then employed Mendelian randomization to establish a causal link between increased gene activity and elevated triglycerides and indicators of liver disease.

The drug's significance lies in its targeted approach, affecting LXR alpha receptors only in the liver and intestines, without impacting their function in other tissues. This specificity addresses a challenge that hindered the development of previous drugs due to potential side effects.

According to the World Health Organization, cardiovascular diseases remain the leading cause of death globally, accounting for approximately 20 million deaths annually. Elevated triglycerides are a major risk factor.

The American Heart Association also affirms that high triglycerides are associated with an increased risk of heart disease and stroke, especially when combined with obesity or diabetes.

Despite the positive results, the drug is still in the early stages of clinical development. Researchers are preparing to launch longer trials on individuals with hypertriglyceridemia and metabolic dysfunction-associated fatty liver disease to assess its long-term effectiveness.

The research team cautions that the current findings are preliminary and should be interpreted with caution. However, they pave the way for broader testing that could unlock a new avenue for treating cardiometabolic diseases.